Advertisement


Gary H. Lyman, MD, MPH, on Myeloid Growth Factors: New Biosimilar Approvals

NCCN Annual Conference 2019

Advertisement

Gary H. Lyman, MD, MPH, of the Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance, discusses current strategies for the use of biosimilars to treat cancer-induced anemia and neutropenia, and the need to provide evidence for the efficacy of these agents to allay any concerns about their use.



Related Videos

Breast Cancer

William J. Gradishar, MD, on HR-Positive, HER2-Negative Advanced Breast Cancer: NCCN Guidelines Updates

William J. Gradishar, MD, of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, discusses evidence-based first-line treatment options for patients wi...

Breast Cancer

Melinda L. Telli, MD, on NCCN Guidelines Updates for HR-Positive, HER2-Negative Early-Stage Breast Cancer

Melinda L. Telli, MD, of the Stanford Cancer Institute, discusses the various systemic therapies for patients with early-stage hormone receptor–positive, HER2-negative diseas...

Prostate Cancer

James L. Mohler, MD, on Managing Prostate Cancer: NCCN Guidelines Updates

James L. Mohler, MD, of the Roswell Park Comprehensive Cancer Center, discusses updated recommendations in prostate cancer: more specificity for family history and genomic se...

Skin Cancer

Chrysalyne Schmults, MD, on Basal and Squamous Cell Carcinomas: Trends in Data and Practice

Chrysalyne Schmults, MD, of Brigham and Women’s Hospital, discusses treatment strategies in these nonmelanoma skin cancers, including surgery, forthcoming staging systems, an...

Pancreatic Cancer

Margaret A. Tempero, MD, on Pancreatic Cancer: NCCN Guidelines Updates

Margaret A. Tempero, MD, of the UCSF Helen Diller Family Comprehensive Cancer Center, discusses new adjuvant therapy options for patients with pancreatic cancer, and germline testi...

Advertisement

Advertisement



;
Advertisement